List your practice on InjuredCare | Log in / Sign up

Onglyza

Onglyza

Onglyza was co-formulated by Bristol-Myers Squibb and AstraZeneca in 2007. On July 31, 2009, it was approved by the FDA for treatment of type-2 diabetes. Its key active ingredient, saxagliptin, is a DPP-4 (dipeptidyl peptidase-4) inhibitor. This means it works to prohibit the DPP-4 enzyme from performing its normal function of destroying incretin, which is the hormone responsible for producing insulin and eliminating excess glucose production.

Negative side effects of Onglyza

On April 5, 2016, the FDA issued a warning for type-2 diabetes medications that contain saxagliptin. This safety announcement stated that medications containing saxagliptin lead to an increased risk of heart failure, especially for patients with a history of heart or kidney illnesses. Diabetes medications like Onglyza, which contain saxagliptin, were required to add this warning to their label.

Severe side effects of Onglyza (other than heart failure) can include the following:

  • Low blood sugar
  • Pancreatitis - inflammation of the pancreas
  • Joint pain
  • A rare skin condition (bullous pemphigoid) that causes severe blisters
  • Peripheral edema - fluid retention that leads to swelling of hands, feet, or ankles

Bristol-Myers Squibb and AstraZeneca face over 100 product liability lawsuits

Before Onglyza carried proper warnings on its label, many patients were unknowingly exposed to an increased risk of heart failure. This has led to lawsuits against co-manufacturers Bristol-Myers Squibb and AstraZeneca. Around 100 individual lawsuits from throughout the United States have been consolidated in federal multi-district litigation in the United States District Court for the Eastern District of Kentucky. Other lawsuits also pending in California.

Related Articles

  • Accutane

    Accutane

    A Prescription Medication for the Treatment of Acne Accutane (also marketed as Roaccutane) is the trade or brand name for isotretinoin, a prescription drug used primarily for the Read More...

  • Zoloft

    Zoloft

    Approved by the FDA in 1991, Zoloft is a prescription anti-depressant in the class of selective serotonin reuptake inhibitors (SSRIs). Zoloft's main active ingredient, sertraline, Read More...

  • Failure to Diagnose and Misdiagnosis of Medical Conditions

    Failure to Diagnose and Misdiagnosis of Medical Conditions

    The Common Types of Medical Diagnostic Mistakes When you're experiencing health problems, one of the first things you want and need is an accurate diagnosis of the problem. Unfort Read More...

© 2015-2022 LawConnect, Inc. All rights reserved.

CONCEPT, DESIGN and HOSTING BY GETLEGAL.COM’S WEB SERVICES TEAM..